This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronicpain. Los Angeles, California. www.InvestorBrandNetwork.com.
of the respondents who use it to treat chronicpain, 80% of those reported using it for depression, 73% of respondents with insomnia, and 78.3% The most common health conditions among the sample group were anxiety (51.2%), chronicpain (40.9%), depression (33.1%), and insomnia/distrubed sleep (30.7%).
The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronicpain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. “The 1mg dose showed a significant pain decrease compared to the placebo.
Clinicaltrials into cannabis’ potential as an opioid replacement are well underway in South Africa. According to the announcement, Biodata—a subsidiary of Labat Africa—“is the brainchild of Dr. The pilot results of the study were very promising, as it showed 98% of the patients have some sort of pain relief from cannabis.”.
This may include opiates for chronicpain, anti-nausea medication, and even antidepressants. These symptoms include: Loss of appetite Fatigue or insomnia Nausea and vomiting Constipation Difficulty Breathing Chronicpain Weight loss General weakness of muscle A terminal illness diagnosis can immensely impact a patient and their family.
From chronicpain to neurological disorders, understanding the breadth of MMJ’s applications provides a comprehensive view of its role in modern healthcare. Cannabinoids, the active compounds in marijuana, interact with the endocannabinoid system in the body, modulating pain perception and inflammation.
Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinicaltrials are finding value in the company’s offerings. RYAH Smart inhalers are being used in a huge clinicaltrial based in the UK. Over a five year study, the clinic intends to work with tens of thousands of patients.
(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinicaltrials globally.
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.
Pain Relief Mechanisms and MS Medical marijuana is widely recognized for its analgesic properties, offering relief from neuropathic pain, muscle spasms, and other types of chronicpain commonly experienced by MS patients. More rigorous clinicaltrials are needed to establish clear guidelines for its use in MS management.
Researchers at The University of New Mexico (UNM) have conducted a series of recent studies testing the effectiveness and safety of consuming cannabis, but this is the first study they have conducted measuring the therapeutic potential of hemp oil with low THC levels.
From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions. Studies have suggested that CBD may help manage chronicpain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.
In this article, we explore the role of medical marijuana in addressing insomnia, examining its effectiveness, safety considerations, legal aspects, and practical considerations for patients and healthcare providers. Chronicpain conditions, such as arthritis or back pain, can cause discomfort that interferes with sleep.
And the safety and efficacy of those drugs aren’t even buttressed by a mountain of anecdotal evidence — unlike cannabis use, which has thousands of years of documentation. Just because we don’t yet have clinicaltrial results that confirm medical cannabis relieves pain, or eases insomnia, or reduces inflammation, etc.,
Chronicpain. Chronicpain. Do not offer the following to manage chronicpain in adults: nabilone. Do not offer CBD to manage chronicpain in adults unless as part of a clinicaltrial. Do not offer CBD to manage chronicpain in adults unless as part of a clinicaltrial.
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinicaltrials.
Therapeutic Effects of Cannabinoids Pain Relief: Perhaps one of the most recognized therapeutic effects of cannabinoids is pain relief. Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronicpain conditions such as arthritis, fibromyalgia, and cancer-related pain.
While antiretroviral therapy (ART) has transformed HIV/AIDS from a fatal diagnosis to a manageable chronic condition, patients often endure chronicpain, nausea, appetite loss, and psychological distress. As such, patients report reduced reliance on opioids and other pain medications, which often come with severe side effects.
Medical Uses of THC Let’s explore the diverse medical uses of THC, highlighting its efficacy in alleviating chronicpain, its comparison with traditional painkillers, its role in combating nausea and stimulating appetite, its potential benefits for neurological disorders, and its complex interaction with mental health conditions.
The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronicpain, cancer, arthritis, diabetes, depression, anxiety, and many more. VSN16R was shown to be safe and well-tolerated in its Phase I clinicalsafetytrial. Key Questions Answered.
Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinicaltrials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.
Pain Management Programs : Chronicpain is a common issue among veterans, often stemming from service-related injuries or conditions. While opioids have traditionally been used to manage pain, medical marijuana offers a potentially safer and more effective alternative.
Cannabidiol (CBD) is a well-known component of hemp with diverse health benefits such as reducing pain and inflammation after physical activity, relief from occasional sleeplessness, as well as improvements in focus, mood and resilience to stress. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance.
For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.
as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.
Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinicaltrial protocols and conducting clinicaltrials. The Company’s second drug platform, Supera-CBD , is being developed to treat chronicpain, addiction and epilepsy.
We’re not going to get over the fact that there’s not the same sort of clinicaltrial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. And in my belief, it should be cannabis, because of the safety profile, number one.
The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronicpain, cancer, arthritis, diabetes, depression, anxiety, and many more. VSN16R was shown to be safe and well-tolerated in its Phase I clinicalsafetytrial. INM-755: InMed Pharmaceuticals.
To date, there are several studies that have tried to verify the safety and toxicology of CBD when it is administered to treat certain diseases. Some of the participants in such studies, such as the one conducted to determine the safety and effectiveness of CBD in treating epilepsy , reported the following side effects: Diarrhea.
Examples of claims observed on your website and social media accounts in April 2019 that establish the intended use of your products as drugs include, but may not be limited to, the following: On your product webpage for CBD Disposable Vape Pen (Relieve): • “[F]or chronicpain.”. Chronic or arthritic pain.”. Chronicpain.
Due to the updated hemp act being relatively new, lawmakers are still studying and formulating policies that can better improve the industry while regulating it for the safety of users. Namely, to relieve chronicpains, soothe anxiety, lessen nausea, and even aid them in sleeping better.
Cannabidiol (CBD) is a well-known component of hemp with diverse health benefits such as reducing pain and inflammation after physical activity, relief from occasional sleeplessness, as well as improvements in focus, mood and resilience to stress. Numerous studies have shown that CBD is a safe, non-impairing, and non-habit-forming substance.
I read an op-ed or a column in the New York Times a few weeks ago that totally blew my mind, where this person was basically arguing that we don’t have enough safety information about cannabis in order to be legalizing it everywhere. Sorry, that’s important, safety window. MSO: Yeah. Any cannabis side effect is nothing basically.
However, health professionals have been reluctant to prescribe cannabis-based medicines in the UK because of the lack of clinicaltrial evidence of its benefits and safety. This would answer questions about safety and efficacy, they said. The final guideline is expected to be published in November 2019.
A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety.
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinicaltrials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , ClinicalTrial ID NCT03866174, available at [link].
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Pain and chronicpain were the most common conditions mentioned over the time period and were referred to in 62% of all articles.
As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronicpain but were unable to answer their patients’ questions” (1).
Crohn’s ), chronicpain , appetite loss , issues with sleep , immune system disorders , thermoregulation problems, cancer and more. While there have been significant studies done over the years, only chronicpain, antiemesis, multiple sclerosis , and sleep have any level of evidence of cannabis effectiveness.
Upon completion of all the required IND enabling studies and subsequent review by the FDA, Virpax intends to conduct a Phase 1 study to evaluate the relative bioavailability and pharmacokinetics of Epoladerm™ Virpax recently announced the execution of a clinicaltrial agreement with Altasciences Company, Inc.,
“There’s still a lot we don’t know about medicinal cannabis … when it comes to the pharmacology, what does it do on a molecular level and how does it affect things like chronicpain or symptoms of MS [multiple sclerosis]?”. More recent studies have demonstrated, however, a plausible rationale for therapeutic action.[
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content